Intense Pulse Light for Treating Post-LASIK Refractory Dry Eye

Abstract

Objective:

Optimal pulse technology-intense pulse light (OPT-IPL) treatment on patients with post-LASIK refractory dry eye (DE).

Background:

The prevalence of dry eye disease is common and can lead to ocular discomfort, reduced visual acuity, lowered quality of vision and life.

Materials and methods:

A prospective study was conducted on 72 eyes of 36 patients (treatment group, n = 42 eyes; control group, n = 30 eyes) who had previously undergone myopic LASIK correction with subsequent refractory DE. All eyes fulfilled the Japanese DE criteria and had not responded to conventional DE treatment. The treatment group underwent two OPT-IPL treatment sessions at 2-week intervals, while the control group received no treatment. Best-corrected visual acuity (BCVA), ocular surface disease index (OSDI), noninvasive breakup time (NITBUT), tear film lipid layer (TFLL) quality, corneal fluorescein staining, meibum gland (MG), endothelial cell count (ECC), and intraocular pressure (IOP) were assessed at baseline (D0), day-14 (D14) and day-28 (D28) after OPT-IPL treatment.

Results:

The mean age of treatment group and control group was 30.48 ± 5.16 years (12 females, 57%) and 31.00 ± 4.33 years (8 females, 53%), respectively. Treatment group had clinically and statistically significant improvement in NITBUT and was observed at D14 (p < 0.001) and D28 (p < 0.001). OSDI, TFLL score, and MG quality and expressibility improved significantly (p < 0.05) at D28, whereas BCVA, ECC, and IOP showed no significant changes at D14 and D28 between the groups.

Conclusions:

Our results suggest that post-LASIK refractory DE is safely treated with OPT-IPL treatment. OPT-IPL treatment reduced the severity of symptoms and improved the overall tear film stability in patients with severe refractory DE post-LASIK surgery. In addition, the frequency of artificial tears usage was significantly less and can be attributed to the reduction in OSDI scores due to improved TFLL and tear film stability.

Get full access to this article

View all access options for this article.

References

McGinnigle

, Naroo

, Eperjesi

. Evaluation of dry eye. Surv Ophthalmol, 2012; 57:293–316.

, Pazo

, Zou

, Jin

Prevalence of symptomatic dry eye in breast cancer patients undergoing systemic adjuvant treatment: a cross-sectional study. Breast, 2020. [Epub ahead of print]; DOI: 10.1016/j.breast.2020.07.009

Moss

, Klein

. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol, 2000; 118:1264.

Toda

Dry eye after lasik. Investig Ophthalmol Vis Sci, 2018; 59:DES109–DES115.

Albietz

, Lenton

. Management of the ocular surface and tear film before, during, and after laser in situ keratomileusis. J Refract Surg, 2004; 20:62–71.

G.R. N, S.C. P. Post-LASIK tear dysfunction and dysesthesia. Ocul Surf, 2010; 8:135–145.

Holly

FJ.

Formation and rupture of the tear film. Exp Eye Res, 1973; 15:515–525.

Greiner

JV.

Long-term (12-month) improvement in meibomian gland function and reduced dry eye symptoms with a single thermal pulsation treatment. Clin Exp Ophthalmol, 2013; 41:524–530.

Blackie

, Solomon

, Scaffidi

, Greiner

, Lemp

, Korb

. The relationship between dry eye symptoms and lipid layer thickness. Cornea, 2009; 28:789–794.

10.

Patel

, Pérez-Santonja

, Alió

, Murphy

. Corneal sensitivity and some properties of the tear film after laser in situ keratomileusis. J Refract Surg, 2001; 17:17–24.

11.

Simmons

, Carlisle-Wilcox

, Chen

, Liu

, Vehige

. Efficacy, safety, and acceptability of a lipid-based artificial tear formulation: a randomized, controlled, multicenter clinical trial. Clin Ther, 2015; 37:858–868.

12.

Niamprem

, Teapavarapruk

, Srinivas

, Tiyaboonchai

. Impact of nanostructured lipid carriers as an artificial tear film in a rabbit evaporative dry eye model. Cornea, 2019; 38:485–491.

13.

Maïssa

, Guillon

, Simmons

, Vehige

. Effect of castor oil emulsion eyedrops on tear film composition and stability. Contact Lens Anterior Eye, 2010; 33:76–82.

14.

Craig

, Nichols

, Akpek

, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf, 2017; 15:276–283.

15.

Raulin

, Greve

, Medicine HG-L in

S and

, 2003 U. IPL technology: a review. Wiley Online Libr https://onlinelibrary.wiley.com/doi/abs/10.1002/lsm.10145. Accessed February 22, 2019 .

16.

Heymann

WR.

Intense pulsed light. J Am Acad Dermatol, 2007; 56:466–467.

17.

Gupta

, Vora

, Matossian

, Kim

, Stinnett

. Outcomes of intense pulsed light therapy for treatment of evaporative dry eye disease. Can J Ophthalmol, 2016; 51:249–253.

18.

Toyos

, McGill

, Briscoe

. Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction; a 3-year retrospective study. Photomed Laser Surg, 2015; 33:41–46.

19.

, Lin

, Cheng

. Intense pulsed light treatment for meibomian gland dysfunction in skin types III/IV. Photobiomodul Photomed Laser Surg, 2019; 37:70–76.

20.

Toyos

, Toyos

, Willcox

, Mulliniks

, Hoover

. Evaluation of the safety and efficacy of intense pulsed light treatment with meibomian gland expression of the upper eyelids for dry eye disease. Photobiomodul Photomed Laser Surg, 2019; 37:527–531.

21.

Uchino

, Uchino

, Dogru

, Ward

, Yokoi

, Tsubota

. Changes in dry eye diagnostic status following implementation of revised Japanese dry eye diagnostic criteria. Jpn J Ophthalmol, 2012; 56:8–13.

22.

Nichols

, Foulks

, Bron

, et al. The international workshop on meibomian gland dysfunction: executive summary. Investig Ophthalmol Vis Sci, 2011; 52:1922–1929.

23.

Asbell

, Stapleton

, Wickström

, et al. The international workshop on meibomian gland dysfunction: report of the clinical trials subcommittee. Investig Ophthalmol Vis Sci, 2011; 52:2065–2085.

24.

Fan

, Pazo

, You

, et al. Subjective quality of vision in evaporative dry eye patients after intense pulsed light. Photobiomodul Photomed Laser Surg, 2020. [Epub ahead of print]; DOI: 10.1089/photob.2019.4788.

25.

Stapleton

, Alves

, Bunya

, et al. TFOS DEWS II Epidemiology Report. Ocul Surf, 2017; 15:334–365.

26.

Montés-Micó

, Alió

, Charman

. Dynamic changes in the tear film in dry eyes. Investig Ophthalmol Vis Sci, 2005; 46:1615–1619.

27.

Findlay

, Reid

. Dry eye disease: when to treat and when to refer. Aust Prescr, 2018; 41:160.

28.

Shtein

RM.

Post-LASIK dry eye. Expert Rev Ophthalmol, 2011; 6:575–582.

29.

Tai

, Sun

. Effects of flap diameter on dry eye parameters and corneal sensation after femtosecond laser-assisted LASIK. Taiwan J Ophthalmol, 2019; 9:166–172.

30.

Maychuk

DY.

Prevalence and severity of dry eye in candidates for laser in situ keratomileusis for myopia in Russia. J Cataract Refract Surg, 2016; 42:427–434.

31.

Shen

, Shi

, Yu

, Lin

, Yao

. Small incision lenticule extraction (SMILE) versus femtosecond laser-assisted in situ keratomileusis (FS-LASIK) for myopia: a systematic review and meta-analysis. Li W, ed. PLoS One, 2016; 11:e0158176.

32.

Pietilä

, Huhtala

, Mäkinen

, et al. Uncorrected visual acuity, postoperative astigmatism, and dry eye symptoms are major determinants of patient satisfaction: a comparative, real-life study of femtosecond laser in situ keratomileusis and small incision lenticule extraction for myopia. Clin Ophthalmol, 2018; 12:1741–1755.

33.

Toda

, Kamiyama

, Sakai

, Goto

, Tsubota

. Efficacy of disposable eyelid warming device for the treatment of post-LASIK dry eye. Invest Ophthalmol Vis Sci, 2004; 45:186.

34.

, Lin

S-B

, Zhang

M-Z

, Cheng

. Preliminary assessment of intense pulsed light treatment on the upper eyelids for meibomian gland dysfunction. Photobiomodul Photomed Laser Surg, 2020; 38:249–254.

35.

Goto

, Dogru

, Fukagawa

, et al. Successful tear lipid layer treatment for refractory dry eye in office workers by low-dose lipid application on the full-length eyelid margin. Am J Ophthalmol, 2006; 142:264–270.e1.

36.

Ousler

, Michaelson

, Christensen

. An evaluation of tear film breakup time extension and ocular protection index scores among three marketed lubricant eye drops. Cornea, 2007; 26:949–952.

37.

Foulks

GN.

The correlation between the tear film lipid layer and dry eye disease. Surv Ophthalmol, 2007; 52:369–374.

38.

Mudgil

Antimicrobial role of human meibomian lipids at the ocular surface. Investig Opthalmology Vis Sci, 2014; 55:7272.

39.

O'Neil

, Henderson

, Massaro-Giordano

, Bunya

. Advances in dry eye disease treatment. Curr Opin Ophthalmol, 2019; 30:166–178.

40.

Lam

, Shih

, Fong

, et al. A review on evidence-based treatments for meibomian gland dysfunction. Eye Contact Lens, 2020; 46:3–16.